Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.
Al-Khawaldeh I, Al Yasiri MJ, Aldred GG, Basmadjian C, Bordoni C, Harnor SJ, Heptinstall AB, Hobson SJ, Jennings CE, Khalifa S, Lebraud H, Martin MP, Miller DC, Shrives HJ, de Souza JV, Stewart HL, Temple M, Thomas HD, Totobenazara J, Tucker JA, Tudhope SJ, Wang LZ, Bronowska AK, Cano C, Endicott JA, Golding BT, Hardcastle IR, Hickson I, Wedge SR, Willmore E, Noble MEM, Waring MJ. Al-Khawaldeh I, et al. Among authors: golding bt. J Med Chem. 2021 Jul 22;64(14):10001-10018. doi: 10.1021/acs.jmedchem.0c01249. Epub 2021 Jul 2. J Med Chem. 2021. PMID: 34212719
Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP).
Barlow HC, Bowman KJ, Curtin NJ, Calvert AH, Golding BT, Huang B, Loughlin PJ, Newell DR, Smith PG, Griffin RJ. Barlow HC, et al. Among authors: golding bt. Bioorg Med Chem Lett. 2000 Mar 20;10(6):585-9. doi: 10.1016/s0960-894x(00)00053-6. Bioorg Med Chem Lett. 2000. PMID: 10741559
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble ME, Sausville EA, Schultz R, Yu W. Arris CE, et al. Among authors: golding bt. J Med Chem. 2000 Jul 27;43(15):2797-804. doi: 10.1021/jm990628o. J Med Chem. 2000. PMID: 10956187
Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine.
Griffin RJ, Arris CE, Bleasdale C, Boyle FT, Calvert AH, Curtin NJ, Dalby C, Kanugula S, Lembicz NK, Newell DR, Pegg AE, Golding BT. Griffin RJ, et al. Among authors: golding bt. J Med Chem. 2000 Nov 2;43(22):4071-83. doi: 10.1021/jm000961o. J Med Chem. 2000. PMID: 11063604
Designing inhibitors of cyclin-dependent kinases.
Hardcastle IR, Golding BT, Griffin RJ. Hardcastle IR, et al. Among authors: golding bt. Annu Rev Pharmacol Toxicol. 2002;42:325-48. doi: 10.1146/annurev.pharmtox.42.090601.125940. Annu Rev Pharmacol Toxicol. 2002. PMID: 11807175 Review.
187 results